Precigen (PGEN) Notes Payables (2022 - 2023)
Precigen (PGEN) reported Notes Payables of $13.8 million for Q1 2023, down 68.03% quarter-over-quarter from $43.2 million in Q4 2022.
Precigen (PGEN) Notes Payables (2022 - 2023) Analysis & Trends
Precigen (PGEN) has 2 years of Notes Payables data on file, last reported at $13.8 million in Q1 2023.
- Notes Payables for Q1 2023 came in at $13.8 million, changed N/A year-over-year; the trailing twelve-month figure through Mar 2023 was $13.8 million (changed N/A YoY), and the FY2022 annual result was $43.2 million, changed N/A from the prior year.
- Notes Payables declined to $13.8 million in Q1 2023 per PGEN's latest filing, from $43.2 million in the prior quarter.
- Over five years, Notes Payables peaked at $43.2 million in Q4 2022 and troughed at $13.8 million in Q1 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - |
| 10 | Precigen | 1.27 Bn | 1.27 Bn | 20.69 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2023 | 13.82 Mn |
| Dec 31, 2022 | 43.22 Mn |